Пенестер

Quick links to important sections

Пенестер

Selected form

Treatment option: Androgenetic Alopecia, Alopecia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Пенестер

Property Description
Active ingredient Finasteride
Form Film-coated tablet
Pharmacological class 5-alpha-reductase inhibitor
General purpose Modulation of androgen hormone levels
Origin Synthetic compound (4-Aza-steroid derivative)

Defining Пенестер: Classification and Composition

Пенестер is a prescription-only medicine that contains the single active ingredient, Finasteride, provided as a film-coated tablet for oral administration. The medication is manufactured by Gedeon Richter, a long-established European pharmaceutical company. Chemically, Finasteride is identified as a 4-Aza-steroid compound, confirming its synthetic origin and classification within the steroid-related chemical group. This medication is a single-ingredient pharmaceutical product, structured for the systemic absorption required for its action throughout the body.

Пенестер's Pharmacological Class: A Selective Enzyme Inhibitor

Pharmacologically, Пенестер is classified as a selective 5-alpha-reductase inhibitor. Its fundamental function is to specifically block the enzyme 5-alpha-reductase, which is responsible for the conversion of the hormone Testosterone into the significantly more potent androgen, Dihydrotestosterone (DHT). This mechanism is crucial to its therapeutic identity, and its efficacy has been clinically recognized for its targeted impact on hormonal metabolism. A comprehensive review of the drug's action confirms its role as a competitive inhibitor of the 5-alpha-reductase enzyme.

General Purpose and Role in Therapy

The fundamental therapeutic purpose of this medication is to systematically modulate the body’s overall hormonal environment by reducing Dihydrotestosterone (DHT) levels. This specific action is intended to address underlying biological processes that are driven by, or dependent upon, excessive DHT activity. A typical neutral use scenario involves regulating androgen levels in adult males. The systemic administration of Пенестер serves to regulate the androgen balance, providing a pharmacological approach to slow the progression or relieve symptoms associated with androgen-dependent conditions.

Regulatory References

  1. Finasteride - StatPearls - NCBI Bookshelf

What side effects are possible with Пенестер?

The safety profile for Пенестер, which contains Finasteride, is primarily documented through regulatory-classified adverse reactions reported in clinical trials and post-marketing surveillance. Adverse events are grouped by frequency and the body's system-organ class, reflecting the medicine's role as a 5-alpha-reductase inhibitor.

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common (occurring in ge1/100 to <1/10 of patients) and are predominantly related to the reproductive system. These include impotence (erectile dysfunction), decreased libido, decreased ejaculate volume, gynecomastia (breast enlargement), and breast tenderness. Uncommon reactions include ejaculation disorder and rash.

Reactions reported during post-marketing surveillance, where frequency is Not Known, span several systems, including reports of depression, suicidal ideation, testicular pain, male infertility, and rare cases of male breast cancer.

Safety Considerations

The most frequent sexual adverse effects typically appear early in the course of therapy. However, it is officially documented that decreased libido and sexual dysfunction have been reported to persist after discontinuation in some individuals. Finasteride is contraindicated in women who are or may potentially be pregnant due to the risk of external genitalia abnormalities in a male fetus. Consequently, pregnant women must not handle crushed or broken tablets. Treatment also causes a significant decrease in Prostate Specific Antigen (PSA) levels, which requires adjustment when interpreting screening results.

Overdose and Emergency Response

The official regulatory profile for Пенестер (Finasteride) overdose is structured by the absence of specific documented findings and an explicit requirement for immediate emergency action.

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations No specific dose-related undesirable effects were observed.
Physiological systems affected (as stated in label) None explicitly documented in the overdose section of the labeling.
Dose-related or exposure-related factors (if applicable) Clinical trials reported no adverse effects following single doses up to 400 mg and multiple daily doses up to 80 mg/day for three months.
Emergency-response statements (as written in official documents) Contact a Poison Control Centre or seek immediate medical attention even if symptoms are absent.
When immediate medical help is required (label-derived phrasing only) Immediately call emergency services if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose classifications (high-level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Not explicitly classified by severity in the overdose section.
Overdose-context constraints (as defined in official documents) No specific treatment is recommended, indicating management is non-specific.

Resulting overdose structure

Official overdose statements:

  • No specific overdose symptoms are documented as clinical trials did not find dose-related adverse effects.
  • No specific treatment or antidote is recommended by regulatory authorities.
  • Management is limited to providing symptomatic and supportive treatment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by the lack of specific documented clinical findings from high-dose exposure. The profile mandates the immediate seeking of emergency medical assistance, focusing on supportive care for severe, general physiological compromise.

Therapeutic Uses of Пенестер

What Пенестер Treats: Main Uses and Benefits

Пенестер (finasteride) is commonly used across conditions characterized by periods of heightened symptoms related to prostate enlargement. The core therapeutic area is applied in addressing benign prostatic hyperplasia (BPH), which is considered relevant for men experiencing a non-cancerous enlargement of the prostate gland. This agent helps manage symptoms that interfere with daily functioning, such as difficulty or delay in starting urination, a frequent or urgent need to urinate, and a weakened urinary stream.

The medicine plays a role in managing the underlying cause of the enlargement, which contributes to reducing the size of the enlarged prostate. This may assist with maintaining functional stability, offering symptomatic relief that helps patients cope more steadily. The active substance is considered relevant across two therapeutic domains, including benign prostatic hyperplasia and male pattern hair loss (androgenetic alopecia).

“The medicine supports the patient during difficult episodes by easing distress associated with urinary symptoms.”

The management of male pattern hair loss is considered relevant where the medicine provides support that helps ease the overall symptom burden associated with progressive hair thinning.


Quick Fact: Relief for Urinary Symptoms

Regulatory References

  1. NIH DailyMed Official Labeling for Finasteride

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Пенестер (Finasteride) — official regulatory information

The eligibility for Пенестер (Finasteride) is strictly limited to adult males due to its pharmacological classification and regulatory contraindications.


Eligibility Scope

Classification Eligible Population Restriction/Status
Populations Allowed Adult Males (Aged 18 and over) Use is established and approved for labeled indications.
Populations Contraindicated Females The medicine is not indicated for use in women.
Pregnant or Potentially Pregnant Females Strictly contraindicated due to potential risk to a male fetus.
Pediatric Patients (Under 18) Use is not recommended; safety and effectiveness not established.
Patients with known Hypersensitivity Contraindicated to the active substance or any tablet component.
Organ Function Status Renal Impairment No dosage adjustment is necessary, even for severe insufficiency.
Hepatic Impairment Caution is advised, as the medicine is extensively metabolized in the liver.

Resulting Eligibility Structure

The regulatory profile establishes a narrow eligibility window for Пенестер, exclusively permitting its use in adult males who do not have a known allergy to the medication. All females, children, and adolescents are formally contraindicated from use, which reflects the strict eligibility constraints defined in government labeling. Furthermore, specific cautions are applied for patients with liver function abnormalities, while those with renal impairment have no required dosage restriction.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Пенестер

The official interaction profile for finasteride is characterized by specific co-administration restrictions and established metabolic pathways, with an overall finding of no clinically important interactions with common tested compounds.

Category Official Regulatory Statement
Medicinal product categories with documented interactions: 5-alpha-reductase inhibitors (prohibited co-administration); Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers (predicted pharmacokinetic effect).
Mechanistic basis of interactions (only if stated in label): Finasteride is metabolized primarily via the CYP3A4 enzyme subfamily. Modulators of this enzyme are probable to affect plasma concentrations.
Timing-based interaction rules (if applicable): Finasteride bioavailability is not affected by food. Administration may occur with or without food.
Population-specific interaction notes (if applicable): Caution is advised in patients with hepatic insufficiency due to the drug's extensive liver metabolism. No dosage adjustment is required for renal impairment.

Interaction Classifications (High-Level)

  • Interaction severity classification: The drug is generally associated with no drug interactions of clinical importance based on testing with compounds such as Warfarin and Digoxin. Co-administration with other 5-alpha-reductase inhibitors is contraindicated.
  • Interaction-related restrictions: Formal prohibition on co-administering with Finasteride 5 mg or any other 5-alpha-reductase inhibitor. Pregnant women must not handle crushed or broken tablets.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure primarily by noting the absence of clinically important interactions with most tested substances. The profile is further defined by the explicit prohibition against combining it with other 5-alpha-reductase inhibitors and includes a mandatory caution regarding its extensive liver metabolism in patients with hepatic insufficiency.

Mechanism of Action

Targeted Inhibition of the 5-Alpha-Reductase Enzyme

Пенестер ( Finasteride) functions as a selective competitive inhibitor primarily targeting the Type II 5-alpha-reductase (5alpha-R2) enzyme. This molecular step interrupts the specific metabolic pathway responsible for converting Testosterone into the potent androgen, Dihydrotestosterone (DHT). This molecular intervention results in a substantial suppression of DHT production within sensitive peripheral tissues.


Localized Anti-Androgenic Cellular Signaling

The central mechanism leads to a substantial, localized reduction in DHT concentration in target organs like the prostate gland and hair follicles. This depletion limits DHT binding to the Androgen Receptor, causing a shift in cellular signaling away from DHT-driven growth and proliferation. The physiological consequence is the induction of tissue volume reduction or the maintenance of the size of DHT-dependent structures.


⏳ Mechanism-Driven Time-Course

The nature of this enzyme-based mechanism results in a disconnect between the initial molecular action and the final physiological effect. While the suppression of DHT begins rapidly, the resulting physiological changes—such as actual tissue mass reduction—are cumulative processes that depend on the continuous maintenance of the low-androgen state. The complete functional manifestation of the mechanism is gradual, requiring months of sustained action.

Dosage and Administration Information

The administration of Пенестер (finasteride) is determined by the prescribed indication and is structured around a once-daily oral regimen. The medication is provided as a film-coated tablet and is administered by the oral route for systemic action. In some jurisdictions, a topical cutaneous spray solution is also an authorized route for specific use.

The official dosing schedule requires distinct strengths for different use patterns. For benign prostatic hyperplasia (BPH), the standard dose is 5 mg taken once daily. For male pattern hair loss, the established dose is 1 mg taken once daily. Both strengths may be taken with or without food, as the label does not restrict intake timing relative to meals.

The tablets must be swallowed whole and should not be crushed, broken, or divided. This is a critical administration constraint tied to the integrity of the film-coating. Treatment for either indication requires a long-term commitment: assessment of efficacy typically requires use for at least three to six months. If a dose is missed, patients are instructed to skip the forgotten dose and resume the standard schedule at the next designated time, without taking an extra tablet.

Dosing Scope Standard Labeled Instruction
Frequency Once daily for all strengths.
Renal/Geriatric Adjustments No dosage adjustment is required for older adults or patients with renal impairment.
Pediatric Use Not indicated for use in children or adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Пенестер

Evidence for Use in Benign Prostatic Hyperplasia (BPH)

The medicine was studied for use in men with an enlarged prostate (BPH) using large-scale, multi-national Randomized Controlled Trials (RCTs). Research examined outcomes related to physical discomfort and functional imbalance, such as changes in the severity of lower urinary tract symptoms, and objective measurements like maximum urinary flow rate and prostate volume.

Findings describe patterns observed in the studies related to changes documented in symptoms and the size of the prostate gland over defined time intervals. Trials monitored specific outcomes, including changes in the Prostate Specific Antigen (PSA) biomarker, and the frequency of clinical BPH-related events such as the need for surgery. Research describes patterns related to a measurable change in prostate size in the observed populations during the study period.

Evidence for Use in Male Pattern Hair Loss (Androgenetic Alopecia)

The evidence foundation for the use of this medicine in male pattern hair loss (Androgenetic Alopecia) was primarily built upon multi-center Randomized Controlled Trials (RCTs) over short-term intervals (one to two years). Research examined adult men, typically aged 18 to 41, with mild to moderate severity of hair thinning.

Outcomes examined included quantitative measures like the total hair count in a small target area of the scalp, and qualitative measures such as photographic assessments reviewed by expert panels. Studies reported measurements of changes in hair count compared to initial measurements across the primary two-year observation period.

Long-Term Studies and Durability of Research Findings

Long-term follow-up research was conducted for both studied conditions, exploring how symptoms change over time and the persistence of measured outcomes. For BPH, large follow-up and prevention trials extended observation periods up to seven years. For hair loss, specific cohorts were observed for periods up to ten years in open-label settings. This extended research provides context but not individual predictions regarding long-term outcomes.

What is Still Uncertain About the Evidence for Пенестер

Research includes findings related to prostate cancer detection. Research describes that the long-term administration of the medicine was associated with an observed increase in the detection of high-grade prostate cancer in some studies.

Beyond this, data are still emerging regarding certain aspects of both conditions. The research base does not include studies in women or pediatric populations. Follow-up durations were shorter in some early trials, and long-term effects for all outcomes are not fully established.

Key Studies & References

  1. Label: FINASTERIDE tablet, film coated (5 mg) (BPH indication) - DailyMed
  2. Label: FINASTERIDE tablet, film coated (1 mg) (Male Pattern Hair Loss indication) - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Пенестер (FAQ)


Q: Is Пенестер a generic medicine, or a brand name?

Пенестер is the brand name used for this medicine in certain regions and is manufactured by Gedeon Richter. The active ingredient in the tablet is Finasteride. Finasteride is the generic name for the compound, which is also available under several other brand names and as generic tablets.


Q: Is Пенестер classified as a hormonal medicine?

Officially, Пенестер is classified as a selective 5-alpha-reductase inhibitor, meaning it blocks a specific enzyme. This enzyme is responsible for converting the hormone Testosterone into the more potent androgen, Dihydrotestosterone (DHT). While the drug modulates this specific hormone process, its chemical identity is a 4-Aza-steroid compound.


Q: Do side effects from Пенестер typically happen right away or after long-term use?

Official documents focusing on the safety profile indicate that the most common sexual adverse effects tend to appear relatively early in the course of therapy. Other side effects may develop at different times during treatment. This does not preclude the possibility of side effects emerging at any point during continuous use.


Q: Are there specific pre-existing medical conditions that may increase the risk of side effects from Пенестер?

Regulatory warnings advise caution for individuals with pre-existing hepatic insufficiency, which is another term for liver impairment. This caution exists because the medicine is extensively metabolized, or broken down, by the liver. Having impaired liver function could potentially lead to higher-than-expected levels of the drug in the body.


Q: Why do the official warnings mention caution when handling crushed or broken tablets?

Official regulatory documents contain specific instructions that women who are pregnant or may become pregnant must not handle crushed or broken tablets. The active ingredient, Finasteride, can be absorbed through the skin. This could pose a potential risk to a male fetus, potentially causing external genitalia abnormalities.


Q: Can Пенестер be taken with common vitamins or herbal supplements?

Finasteride has not been shown to interfere with most tested prescription medications. However, official guidance reminds patients that herbal remedies and supplements are often not subjected to the same rigorous interaction testing as regulated prescription drugs. For this reason, official sources describe the need to discuss all concurrent medications with a healthcare provider.


Q: Is there research that looks at the use of Пенестер in men under the age of 50?

Research evidence for the use of the 1 mg strength for male pattern hair loss included cohorts of adult men typically ranging in age from 18 to 41 years old. This research established evidence for the medicine’s use within that younger adult population for that specific indication.


Q: Is weight gain an officially listed side effect of Пенестер?

Weight change (either gain or loss) was generally not reported as a common side effect in official clinical trials or post-marketing surveillance reports. Side effects listed most frequently in official documents are primarily related to sexual function and breast issues.


Q: Is there an official warning about drowsiness or the ability to drive when taking Пенестер?

The official documentation indicates that Finasteride is not expected to affect a person's ability to drive or operate machinery. Regulatory safety information does not generally list drowsiness as a common adverse effect.


Q: What general steps are described if a side effect is suspected or experienced?

Patient information describes that for severe symptoms, such as swelling of the face, lips, tongue, or throat, individuals should seek immediate medical attention. This guidance highlights the types of severe symptoms often noted to indicate a serious allergic reaction.


Q: How long does the body typically take to eliminate Пенестер after the last dose?

Official pharmacokinetic data describes the terminal half-life of the medicine. This half-life is approximately five to six hours in younger men, and slightly longer, about eight hours, in men over 70. The half-life refers to the time it takes for half of the drug to be eliminated from the body.


Q: If the use of Пенестер is stopped, how long are its therapeutic effects believed to last?

The intended therapeutic benefit is dependent upon the continuous use of the medication. If the use of the medicine is stopped, the treated condition (such as hair loss or BPH symptoms) is generally expected to gradually revert to the untreated state. This process is often noted to occur within six to twelve months after discontinuation.


Q: Why is alcohol consumption often questioned when taking Пенестер?

Official regulatory documents do not specify a clinical interaction between alcohol and the medicine itself. However, general guidance notes that heavy alcohol consumption can potentially worsen the symptoms of benign prostatic hyperplasia (BPH) or increase the risk of certain side effects.

How should Пенестер be stored and disposed of?

How to Store and Dispose of Пенестер (Finasteride)

The official storage and disposal requirements for Finasteride tablets are defined by regulatory agencies to maintain product stability and ensure public safety.

Storage Requirements

The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted fluctuations. It is mandatory to keep the medication in its original container, tightly closed, and protected from excess heat, moisture, light, and freezing. All tablets must be stored out of the sight and reach of children.

Handling and Disposal

A specific safety instruction requires that women who are or may be pregnant must not handle crushed or broken tablets due to the risk of active ingredient absorption. Expired or unused medicine must be discarded using a drug take-back program. Disposal via wastewater or standard household trash is generally prohibited; consult a pharmacist or local regulatory guidelines for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Пенестер found in:

A-Z Index: